Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 175 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 A Better Biomarker for Cancer Immunotherapy? November 3, 2023 Foodie Fridays: Farmer’s Market Finds July 16, 2021 FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer April 23, 2021 Load more HOT NEWS Research with Integrity – integrating training into research culture Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... Elucidating a Risk of Developing Second Primary Malignancy During and After...
